市場調查報告書

疾病分析:卵巢癌

Disease Analysis: Ovarian Cancer

出版商 Datamonitor Healthcare 商品編碼 939970
出版日期 內容資訊 英文 109 Pages
商品交期: 最快1-2個工作天內
價格
疾病分析:卵巢癌 Disease Analysis: Ovarian Cancer
出版日期: 2020年04月01日內容資訊: 英文 109 Pages
簡介

推定於2018年全球15歲以上的女性有293,300件的卵巢癌病例,這個數量至2027年將為增加至319,500例。使用高度一般化的白金治劑之化學療法,依然是對於新確診患者與復發白金系抗癌劑感受性的卵巢癌患者兩邊的標準治療。

本報告中,調查了卵巢癌,並整理了疾病的背景與患者動向、治療方針、藥劑動向、臨床實驗動向、將來動向等內容。

目次

概要

  • 最新要點

疾病的背景

  • 定義
  • 預後
  • 危險因子
  • 症狀
  • 診斷
  • 患者的市場劃分

治療

  • 照會模式
  • 新確診階段I
  • 新確診階段II或是階段III
  • 新確診階段IV
  • 藥理學的治療:初次化療
  • 藥理學的治療:復發/已復發疾病

流行病學

  • 發生調查方法

市售藥物

管道運輸藥

主要法規活動

  • ImmunoGenゎ FORWARD撤退後、再組成、檢討新型卵巢癌PHASEIII

成功的機率

臨床試驗的情勢

  • 地位別贊助者
  • 階段別贊助者
  • 最新事例

藥物評價模型

市場力學

今後之動向

  • 因新型標靶治療的發售及標籤擴大影響,可促進預測期間中之卵巢癌市場成長
  • 生物標記的狀態對於治療的決定變得更加重要
  • PARP抑制劑仍舊為對卵巢癌內的主要藥物組成
  • 初次治療與初次治療之管理設定之PD-1 / PD-L1抑制劑間的競爭將會更加激烈

最新事例與分析師之見解

  • 對於卵巢癌之複數的藥劑(2020年3月12日)
  • 對於卵巢癌之Acelarin(2020年3月10日)
  • 對於卵巢癌之DPX-Survivac(2020年2月25日)
  • 對於卵巢癌之farletuzumab(2020年1月31日)
  • 對於卵巢癌之AM0010(2020年1月30日)
  • 卵巢癌的Nivolumab(2020年1月24日)
  • 對於卵巢癌之AVB-500(2019年11月20日)
  • 對於卵巢癌之mirvetuximab soravtansine(2019年9月29日)
  • 卵巢癌的Zejula(2019年9月28日)
  • 卵巢癌的veliparib(2019年9月28日)
  • 卵巢癌的Lynparza(2019年9月28日)
  • 對於卵巢癌之AVB-500(2019年9月27日)
  • 對於卵巢癌之M6620(2019年9月27日)
  • 卵巢癌的Lynparza(2019年8月14日)
  • Mavorixafor卵巢癌(2019年7月17日)
  • 卵巢癌的Zejula(2019年7月15日)
  • 對於卵巢癌之magrolimab(2019年7月11日)
  • 卵巢癌的Mvasi(2019年6月25日)
  • 卵巢癌的Lynparza(2019年6月3日)
  • 對於卵巢癌之XMT-1536(2019年6月1日)
  • 卵巢癌的Tivopath(腫瘤學)(2019年6月1日)
  • 對於卵巢癌之mirvetuximab soravtansine(2019年5月15日)
  • 對於卵巢癌之mirvetuximab soravtansine(2019年5月15日)
  • 卵巢癌的RUBRACA(2019年5月2日)
  • 卵巢癌的OPTUNE(2019年3月22日)
  • 卵巢癌的DCVAC / OvCa(2019年3月19日)
  • 對於卵巢癌的複數藥品(2019年3月19日)
  • 對於卵巢癌的DKN-01(2019年3月18日)

共識決測法預測

今後主要的活動

主要意見領袖的訪問

未滿足之需求

  • 鉑金耐受性/難治性卵巢癌的治療
  • 為求早期驗出所做的測試改善

參考文獻

  • 處方箋情報

附錄

目錄
Product Code: DMKC0215129

Latest key takeaways

Datamonitor Healthcare estimates that in 2018, there were 293,300 incident cases of ovarian cancer worldwide in females aged 15 years and older, and forecasts that number to increase to 319,500 cases by 2027. Highly genericized platinum-containing chemotherapies are still the standard of care for both newly diagnosed and recurrent platinum-sensitive ovarian cancer patients.

The overall likelihood of approval of a Phase I ovarian cancer asset is 4.4%, and the average probability a drug advances from Phase III is 27.3%. Ovarian cancer drugs, on average, take 10.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

Avastin has become the drug of choice for the maintenance treatment of ovarian cancer patients who do not have a BRCA mutation. However, upcoming patent expiries and expected competition from label expansions for the poly (ADP-ribose) polymerase (PARP) inhibitors and late-phase pipeline drugs will challenge Avastin's position in the ovarian cancer market.

The PARP inhibitor Lynparza has quickly become the standard of care first-line maintenance therapy for patients with BRCA mutated ovarian cancer in the US and EU. However, the PARP inhibitors Zejula and veliparib will soon compete with Lynparza in this treatment setting. Although all three PARP inhibitors have also demonstrated an advantage over chemotherapy in patients without a BRCA mutation or a homologous recombination deficiency (HRD), the primary benefit was derived in patients with BRCA or other HRD mutations, which may limit uptake in the broader patient population.

Rubraca, another PARP inhibitor, has experienced only moderate uptake in the US and the EU as a maintenance treatment for recurrent platinum-sensitive ovarian cancer, and in the US as a third-line or later treatment for BRCA mutation-positive (BRCAm+) patients. However, a potential combination with Opdivo in the first-line maintenance setting may expand Rubraca's commercial potential.

New product launches will play a pivotal part in future market dynamics over the next decade. Key new product launches will include checkpoint inhibitors, folate receptor alpha (FRα)-directed antibody-drug conjugate mirvetuximab soravtansine, the targeted anti-cancer viral-based gene therapy agent ofranergene obadenovec, and the VEGF inhibitor Recentin.

The inclusion of PARP inhibitors in the treatment paradigm has led to a subsequent increase in testing for germline and somatic BRCA1/2 mutations as well as genomic instability score (GIS). This trend of using biomarkers to inform treatment decisions will continue with the introduction of checkpoint inhibitors and mirvetuximab soravtansine, which will likely require PD-L1 and FRα testing, respectively.

Several PD-1/PD-L1 inhibitors - dostarlimab, Opdivo, Keytruda, Tecentriq, and Imfinzi - are in late-phase development in combination with carboplatin and paclitaxel with or without concurrent bevacizumab in the front-line and first-line maintenance setting. Because of the likely clinical similarities between drugs within this class, companies developing checkpoint inhibitors will seek to use label expansions into other treatment settings, such as the recurrent setting, to differentiate their products and increase the size of the potential patient population.

As platinum resistance continues to be the primary contributor to mortality in ovarian cancer patients, effective treatments for platinum-resistant or platinum-refractory ovarian cancer remain the largest unmet need within the indication. Treatment for platinum-resistant/refractory ovarian cancer is largely palliative and patients currently have very limited treatment options.

There are no routine screening methods recommended by medical or professional organizations because screening techniques using single tests or combined algorithms have not been shown to reduce all-cause or disease-specific morbidity or mortality. Research to address this unmet need through the development of reliable screening and diagnostic tools that detect early-stage ovarian cancer is ongoing.

Key recent events include Opdivo's Phase III failure as a monotherapy treatment for platinum-refractory recurrent ovarian cancer in ONO-4538-23, and a positive subgroup analysis for mirvetuximab soravtansine in the Phase III FORWARD I study.

Key upcoming catalysts for 2020 include topline results for the Phase III IMagyn050 study of Tecentriq and Avastin, the Phase III OVAL study of ofranergene obadenovec and paclitaxel, and the pivotal Phase II CONCERTO study of Recentin and Lynparza.

TABLE OF CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition
  • Prognosis
  • Risk factors
  • Symptoms
  • Diagnosis
  • Patient segmentation

TREATMENT

  • Referral patterns
  • Newly diagnosed Stage I
  • Newly diagnosed Stage II or Stage III
  • Newly diagnosed Stage IV
  • Pharmacological treatment: first-line
  • Pharmacological treatment: recurrent/relapsed disease

EPIDEMIOLOGY

  • Incidence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • ImmunoGen Regroups After FORWARD Setback, Looks To New Ovarian Cancer Phase III

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

  • Launches of new targeted therapies and label expansions will drive growth in the ovarian cancer market over the forecast period
  • Biomarker status will become increasingly important in treatment decisions
  • PARP inhibitors will remain the leading drug class within ovarian cancer
  • Competition will be fierce between PD-1/PD-L1 inhibitors in the first-line and first-line maintenance settings

RECENT EVENTS AND ANALYST OPINION

  • Multiple Drugs for Ovarian Cancer (March 12, 2020)
  • Acelarin for Ovarian Cancer (March 10, 2020)
  • DPX-Survivac for Ovarian Cancer (February 25, 2020)
  • Farletuzumab for Ovarian Cancer (January 31, 2020)
  • Pegilodecakin for Ovarian Cancer (January 30, 2020)
  • Opdivo for Ovarian Cancer (January 24, 2020)
  • AVB-500 for Ovarian Cancer (November 20, 2019)
  • Mirvetuximab Soravtansine for Ovarian Cancer (September 29, 2019)
  • Zejula for Ovarian Cancer (September 28, 2019)
  • Veliparib for Ovarian Cancer (September 28, 2019)
  • Lynparza for Ovarian Cancer (September 28, 2019)
  • AVB-500 for Ovarian Cancer (September 27, 2019)
  • M6620 for Ovarian Cancer (September 27, 2019)
  • Lynparza for Ovarian Cancer (August 14, 2019)
  • Mavorixafor for Ovarian Cancer (July 17, 2019)
  • Zejula for Ovarian Cancer (July 15, 2019)
  • Magrolimab for Ovarian Cancer (July 11, 2019)
  • Mvasi for Ovarian Cancer (June 25, 2019)
  • Lynparza for Ovarian Cancer (June 3, 2019)
  • XMT-1536 for Ovarian Cancer (June 1, 2019)
  • Tivopath (Oncology) for Ovarian Cancer (June 1, 2019)
  • Mirvetuximab Soravtansine for Ovarian Cancer (May 15, 2019)
  • Mirvetuximab Soravtansine for Ovarian Cancer (May 15, 2019)
  • Rubraca for Ovarian Cancer (May 2, 2019)
  • Optune for Ovarian Cancer (March 22, 2019)
  • DCVAC/OvCa for Ovarian Cancer (March 19, 2019)
  • Multiple Drugs for Ovarian Cancer (March 19, 2019)
  • DKN-01 for Ovarian Cancer (March 18, 2019)

CONSENSUS FORECASTS

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

UNMET NEEDS

  • Treating platinum-resistant/refractory ovarian cancer
  • Improved testing for earlier detection

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of ovarian cancer, 2018-27
  • Figure 2: Overview of pipeline drugs for ovarian cancer in the US
  • Figure 3: Pipeline drugs for ovarian cancer, by company
  • Figure 4: Pipeline drugs for ovarian cancer, by drug type
  • Figure 5: Pipeline drugs for ovarian cancer, by classification
  • Figure 6: Probability of success in the ovarian cancer pipeline
  • Figure 7: Clinical trials in ovarian cancer
  • Figure 8: Top 10 drugs for clinical trials in ovarian cancer
  • Figure 9: Top 10 companies for clinical trials in ovarian cancer
  • Figure 10: Trial locations in ovarian cancer
  • Figure 11: Ovarian cancer trials status
  • Figure 12: Ovarian cancer trials sponsors, by phase
  • Figure 13: Datamonitor Healthcare's drug assessment summary for ovarian cancer
  • Figure 14: Market dynamics in ovarian cancer
  • Figure 15: Future trends in ovarian cancer
  • Figure 16: Lynparza and Recentin for Ovarian Cancer (March 12, 2020): Phase III - GY004 (w/Cediranib)
  • Figure 17: Acelarin for Ovarian Cancer (March 10, 2020): Phase II - PRO105
  • Figure 18: DPX-Survivac for Ovarian Cancer (February 25, 2020): Phase Ib/II - DeCidE1
  • Figure 19: Opdivo for Ovarian Cancer (January 24, 2020): Phase III - ONO-4538-23
  • Figure 20: Mirvetuximab Soravtansine for Ovarian Cancer (September 29, 2019): Phase III - FORWARD I
  • Figure 21: Zejula for Ovarian Cancer (September 28, 2019): Phase III - PRIMA
  • Figure 22: Zejula for Ovarian Cancer (September 28, 2019): Phase III - PRIMA
  • Figure 23: Veliparib for Ovarian Cancer (September 28, 2019): Phase III - VELIA (w/Carboplatin/paclitaxel)
  • Figure 24: Lynparza for Ovarian Cancer (September 28, 2019): Phase III - PAOLA-1
  • Figure 25: M6620 for Ovarian Cancer (September 27, 2019): Phase II - w/Gemcitabine
  • Figure 26: Lynparza for Ovarian Cancer (August 14, 2019): Phase III - PAOLA-1
  • Figure 27: Zejula for Ovarian Cancer (July 15, 2019): Phase III - PRIMA
  • Figure 28: Lynparza for Ovarian Cancer (June 3, 2019): Phase III - SOLO 3 (BRCA Mutation; Relapsed) - vs. Chemotherapy
  • Figure 29: XMT-1536 for Ovarian Cancer (June 1, 2019): Phase Ib - First-in-Human (NaPi2b)
  • Figure 30: Tivopath (Oncology) for Ovarian Cancer (June 1, 2019): Phase II - TIVO (Ovarian Cancer)
  • Figure 31: Mirvetuximab Soravtansine for Ovarian Cancer (May 15, 2019): Phase Ib/II - FORWARD II
  • Figure 32: DCVAC/OvCa for Ovarian Cancer (March 19, 2019): Phase II - SOV02 (Carboplatin and Gemcitabine)
  • Figure 33: DKN-01 for Ovarian Cancer (March 18, 2019): Phase II - Gynecologic Malignancies (P204)
  • Figure 34: Key upcoming events in ovarian cancer (Figure 1 of 2)
  • Figure 35: Key upcoming events in ovarian cancer (Figure 2 of 2)

LIST OF TABLES

  • Table 1: Patient segmentation, by FIGO stage
  • Table 2: Incident cases of ovarian cancer, 2018-27
  • Table 3: Marketed drugs for ovarian cancer
  • Table 4: Pipeline drugs for ovarian cancer
  • Table 5: Multiple Drugs for Ovarian Cancer (March 12, 2020)
  • Table 6: Acelarin for Ovarian Cancer (March 10, 2020)
  • Table 7: DPX-Survivac for Ovarian Cancer (February 25, 2020)
  • Table 8: Farletuzumab for Ovarian Cancer (January 31, 2020)
  • Table 9: Pegilodecakin for Ovarian Cancer (January 30, 2020)
  • Table 10: Opdivo for Ovarian Cancer (January 24, 2020)
  • Table 11: AVB-500 for Ovarian Cancer (November 20, 2019)
  • Table 12: Mirvetuximab Soravtansine for Ovarian Cancer (September 29, 2019)
  • Table 13: Zejula for Ovarian Cancer (September 28, 2019)
  • Table 14: Veliparib for Ovarian Cancer (September 28, 2019)
  • Table 15: Lynparza for Ovarian Cancer (September 28, 2019)
  • Table 16: AVB-500 for Ovarian Cancer (September 27, 2019)
  • Table 17: M6620 for Ovarian Cancer (September 27, 2019)
  • Table 18: Lynparza for Ovarian Cancer (August 14, 2019)
  • Table 19: Mavorixafor for Ovarian Cancer (July 17, 2019)
  • Table 20: Zejula for Ovarian Cancer (July 15, 2019)
  • Table 21: Magrolimab for Ovarian Cancer (July 11, 2019)
  • Table 22: Mvasi for Ovarian Cancer (June 25, 2019)
  • Table 23: Lynparza for Ovarian Cancer (June 3, 2019)
  • Table 24: XMT-1536 for Ovarian Cancer (June 1, 2019)
  • Table 25: Tivopath (Oncology) for Ovarian Cancer (June 1, 2019)
  • Table 26: Mirvetuximab Soravtansine for Ovarian Cancer (May 15, 2019)
  • Table 27: Mirvetuximab Soravtansine for Ovarian Cancer (May 15, 2019)
  • Table 28: Rubraca for Ovarian Cancer (May 2, 2019)
  • Table 29: Optune for Ovarian Cancer (March 22, 2019)
  • Table 30: DCVAC/OvCa for Ovarian Cancer (March 19, 2019)
  • Table 31: Multiple Drugs for Ovarian Cancer (March 19, 2019)
  • Table 32: DKN-01 for Ovarian Cancer (March 18, 2019)
  • Table 33: Historical global sales, by drug ($m), 2014-18
  • Table 34: Forecasted global sales, by drug ($m), 2020-24